Table 1. Study cohort information.
| Sample ID | Area of Origin | Age | Gender | COVID-19 diagnosis by RT-PCR | Symptomatic/Asymptomatic | Disease Severity |
|---|---|---|---|---|---|---|
| US1 | US | 32 | Male | Confirmed | Symptomatic | Convalescent |
| US2 | US | 35 | Male | Confirmed | Symptomatic | Convalescent |
| US3 | US | 22 | Female | Confirmed | Symptomatic | Convalescent |
| US4 | US | 61 | Female | Confirmed | Symptomatic | Hospitalized |
| US5 | US | 76 | Male | Confirmed | Symptomatic | Hospitalized |
| US6 | US | 51 | Female | Confirmed | Symptomatic | Hospitalized |
| US7 | US | 60 | Male | Confirmed | Symptomatic | Hospitalized |
| US8 | US | 61 | Female | Confirmed | Symptomatic | Hospitalized |
| US9 | US | 81 | Male | Confirmed | Symptomatic | Hospitalized |
| US10 | US | 79 | Male | Confirmed | Symptomatic | Hospitalized |
| US11 | US | 72 | Male | Confirmed | Symptomatic | Hospitalized |
| US12 | US | 59 | Male | Confirmed | Symptomatic | Hospitalized |
| US13 | US | 76 | Female | Confirmed | Symptomatic | Hospitalized |
| US14 | US | 79 | Female | Confirmed | Symptomatic | Hospitalized |
| US15 | US | 85 | Male | Confirmed | Symptomatic | Hospitalized |
| US16 | US | 31 | Female | Confirmed | Symptomatic | Convalescent |
| US17 | US | 59 | Female | Confirmed | Symptomatic | Convalescent |
| SSA1 | SSA | 26 | Male | Confirmed | Symptomatic | Mild |
| SSA2 | SSA | 31 | Female | Confirmed | Asymptomatic | N/A |
| SSA3 | SSA | 32 | Male | N/A | Asymptomatic | N/A |
| *N1 to N3 | SSA | N/A | N/A | N/A | N/A | N/A |
“*” denotes pre-pandemic negative control plasmas.
“US” denotes United States of America.
“SSA” denotes sub-Saharan Africa.
N/A denotes not-applicable or not-available.